Midatech Pharma Share Chat (MTPH)

Find Your Broker

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Midatech Pharma	LSE:MTPH	London	Ordinary Share	GB00BRTL9B63	ORD 0.005P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.25p	+4.88%	5.375p	5.25p	5.50p	5.375p	5.125p	5.125p	442,029	14:31:51

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	6.8	-17.3	-31.0	-	3.29

Midatech Pharma Share Discussion Threads

Showing 426 to 449 of 450 messages

Chat Pages: 18 17 16 15 14 13 12 11 10 9 8 7 Older

Date	Subject	Author	Discuss
13/1/2019 20:41	Have a listen especially at the end they want to keep the Nasdaq listing hxxp://www.midatechpharma.com/audio/180928%20Midatech%20Pharma.mp3	hope67	Read Full Thread Reply
13/1/2019 20:39	hxxps://www.proac tiveinvestors.co.uk/companies/news/203950/big-names-in-pharma-starting-to-take-note-of-midatech-pharma-s-drug-delivery-technology-203950.html	hope67	Read Full Thread Reply
13/1/2019 20:36	hxxp://www.midatechpharma.com/uploads/investor_files/180927%20Interims%20September%202018%20Final.pdf	hope67	Read Full Thread Reply
11/1/2019 20:12	Worth a read htxp://www.evaluate.com/vantage/articles/interviews/midatech-hopes-find-golden-touch-new-focus	hope67	Read Full Thread Reply
11/1/2019 20:11	Look at the volume on the 10th in the Us hxxp://www.stockhouse.com/companies/quote?symbol=mtp	hope67	Read Full Thread Reply
11/1/2019 20:10	1 November 2018 Midatech Pharma PLC ("Midatech", "Company" or "Group") NASDAQ Minimum Bid Price Extension Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, announces that, as previously disclosed, on 1 May, 2018, Midatech Pharma PLC (the "Company") received a letter ("Notification Letter") from The Nasdaq Stock Market LLC ("NASDAQ") providing notification that, for the previous 30 consecutive business days, the bid price for the Company's American Depositary Shares had closed below the minimum $1.00 bid price per share requirement for continued listing on The NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2). Each American Depositary Share represents two ordinary shares of the Company. On 30 October 2018, the Company was notified by NASDAQ that its American Depositary Shares have not regained the minimum $1.00 bid price per share requirement within the 180 calendar days following receipt of the Notification Letter. However, NASDAQ has determined that the Company is eligible for an additional 180 calendar day period, pursuant to NASDAQ Listing Rule 5810(c)(3)(A), or until 29 April 2019, to regain the minimum $1.00 bid price per share requirement. This will be met if, at any time during this 180 days period, the closing bid price of the Company's American Depositary Shares is at least $1.00 for a minimum of ten consecutive business days.	hope67	Read Full Thread Reply
10/1/2019 15:55	250k in at 6.5p - There is a BUYER and SELLER here -	tomboyb	Read Full Thread Reply
10/1/2019 15:53	6.49p is ask now -	tomboyb	Read Full Thread Reply
10/1/2019 15:14	Rake - Looks like NOBBY is correct - Nobbygnome10 Jan '19 - 13:13 - 233 of 238 0 2 0 tomboy I think you are wrong in your comparison of prices. One ADS is equivalent to 2 shares on AIM so the price should be around 8p based on the US price.	tomboyb	Read Full Thread Reply
10/1/2019 14:37	Current price is 0.20c which equates to around 16 pence	rakepat37	Read Full Thread Reply
10/1/2019 14:27	Lets see what the market over at U.S makes of the news today - Selling at 6.75p when the market across the pond is around 8pish mark - Will look to add further on any weakness -	tomboyb	Read Full Thread Reply
10/1/2019 13:52	Check out the 5 dollers price target http://s1.q4cdn.com/460208960/files/News/2018/Zacks_SCR_Research_10032018_MTP_Bautz.pdf	rakepat37	Read Full Thread Reply
10/1/2019 13:38	yes I see now. thanks.	babbler	Read Full Thread Reply
10/1/2019 13:19	Nobby - Thanks - If u see my previous posts i was asking the question of that discrepancy - We are still below that share price (which is why i said i could not understand it and went in blindly at 6.25p) -	tomboyb	Read Full Thread Reply
10/1/2019 13:13	tomboy I think you are wrong in your comparison of prices. One ADS is equivalent to 2 shares on AIM so the price should be around 8p based on the US price.	nobbygnome	Read Full Thread Reply
10/1/2019 12:36	Check out @portefeuillefun's Tweet: https://twitter.com/portefeuillefun/status/1083340718691762177?s=09	aba978731dom	Read Full Thread Reply
10/1/2019 12:34	Back into ths 8p range here - Discrepancy is massive - It should certainly not be so - Which begs the question of MARKET MAKERS and arbitrage -	tomboyb	Read Full Thread Reply
10/1/2019 12:33	And now fully funded ... time to catch up to 16p	rakepat37	Read Full Thread Reply
10/1/2019 12:20	convert it from dollars to GBP. What does the price equate to? Either a massive fall there or we need to catch up.	babbler	Read Full Thread Reply
10/1/2019 12:14	Look at the price it's worth 16p	rakepat37	Read Full Thread Reply
10/1/2019 12:07	What am i missing here. When I look at the nasdaq chart it shows 16% rise not the 100% people are talking about....	pilkersa	Read Full Thread Reply
10/1/2019 12:03	Well I bought on the shake. us open soon...	babbler	Read Full Thread Reply
10/1/2019 11:30	Idiotic punters are helping the MMs out by bailing out. Make their pips squeak!	nobbygnome	Read Full Thread Reply
10/1/2019 10:49	OT) Please look at Futura Medical (FUM) has a dirt low market cap of 22 Million and 3 Drugs including a potential MEGA Blockbuster in Phase 3 trial which is light years better than Viarga and Cialis . If you look for a potential 10+ Bagger then load up FUM Research Confirms MED2002's US$1 Billion Potential hxxps://futuramedical.com/content/news/archive17/060317b.asp The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time. Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide. Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life. The Ipsos valuation was based on the outcomes from primary market research carried out amongst 400 men with ED or suspected ED in the USA. The respondents were in four groups: satisfied users of PDE5 inhibitors (the class of drugs such as Viagra and Cialis); dissatisfied users of PDE5 inhibitors; diagnosed but untreated ED sufferers; and suspected though undiagnosed ED sufferers. The respondents were shown a concept about MED2002 as part of the market research though they did not use the product as it is currently in clinical development. The key findings of the market research showed that the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs. MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action. The Ipsos healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in 9 out of 10 of its forecasts. Pipeline hxxps://www.futuramedical.com/media/144144/Pipeline-2018.jpg MED2002 (topical treatment for erectile dysfunction) hxxps://futuramedical.com/content/products/med_2002.asp first patient dosed: in Q3/Q4 2018 Last patient dosed: by end of June 2019 Headline efficacy results: by end of December 2019 CSD500: Erectogenic condom hxxps://futuramedical.com/content/products/csd_500.asp Significant milestone achieved with approval of 2-year shelf life approved for CSD500, the erectogenic condom in September 2018. Development now complete. Discussions are ongoing with current and potential further distribution partners on next steps with the product in a number of markets. Pain relief products: TPR100 (diclofenac) and TIB200 (ibuprofen) hxxps://futuramedical.com/content/products/tpr_100.asp TPR100 commercial partner Thornton & Ross filed for UK regulatory submission in July 2018. Out-licensing discussions for TPR100 outside of the UK are ongoing.	bioking	Read Full Thread Reply

Chat Pages: 18 17 16 15 14 13 12 11 10 9 8 7 Older